The difference between domestic melphalan/melphalan for injection and imported melphalan

There are some important differences between domestically produced Melphalan for injection/Melphalan (Melphalan flufenamide) and imported melphalan in the market, especially in terms of drug availability, production technology, regulatory standards and clinical application.

Judging from the market access situation, imported melphalan, as the original drug, has been approved and launched in the international market. However, according to current information, domestically produced injectable melphalan is not yet on the market, which means that domestic patients are temporarily unable to obtain this treatment option. Imported drugs usually undergo rigorous clinical trials and regulatory review and are considered to have good data support in terms of efficacy and safety. Domestic drugs also need to undergo relevant clinical trials and reviews before being launched on the market, but because they have not yet been launched, specific efficacy and safety data cannot yet be provided.

In terms of production technology, the production technology and quality control system of imported melphalan generally follow international advanced standards. This means that the production process has strict requirements on the selection of raw materials, control of the production process and quality inspection of the final product. In China, domestically produced melphalan for injection may be developed with reference to these international standards, but due to the lack of actual products on the market, its specific production process and quality control are still unclear. In addition, the research and development process of domestically produced drugs may be affected by local resources, technology levels and policy environment, resulting in differences from imported drugs in some aspects.

In addition, in terms of clinical application, the therapeutic effects and side effects of imported melphalan have been verified in clinical studies in many countries, forming certain clinical practice experience. Although domestically produced melphalan for injection has potential, it has not yet been marketed, and the actual data on its clinical application is still zero. Therefore, when doctors choose treatment options, they may prefer imported drugs that are supported by existing data.